Menu

Oncology Clinical Trials

Call for more information: 770-219-9010

Explore our current clinical trials for oncology:

All Tumor Types

DCP-001

Use of a clinical trial screening tool to address cancer health disparities in the nci community oncology research program (ncorp).

Link

EAY131-MATCH

Molecular analysis for therapy choice (nci-match)

Link

PRO 02-MY PATHWAY

An open-label, phase iia study evaluating trastuzumab,/pertuzumab, erlotinib, vemurafenib/ cobimetinib, vismodegib, alectinib and atezolizumab in patients who have advanced solid tumors with mutations predictive of response to one of these agents.

Link

Brain

A221101

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma .

Link

BRE 203

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR).

Link

S1207

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and her2/neu negative breast cancer.

Link

Colorectal

S0820-PACES

A double blind phase III placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenoma and second primary colorectal cancers in patients with stage 0-III colon cancer.

Link

GYN

724

Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy.

Link

GOG 0238

A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus.

Link

GOG 0225

Can diet and physical activity modulate ovarian, fallopian tube and primary peritoneal cancer progression-free survival?

Link

GOG 0263

Randomized phase iii clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage i/iia cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy.

Link

GOG 3015 (YO39523)

A phase III, multicenter, randomized, study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage iii or stage iv ovarian, fallopian tube, or primary peritoneal cancer.

Link

Lung

A151216 (ALCHEMIST-Main)

Adjuvant lung cancer enrichment marker identification and sequencing trial (alchemist).

Link

A081105 (ALCHEMIST Component)

Randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (egfr) mutant non-small cell lung cancer (nsclc).

Link

S1400

Phase II/III biomarker-driven master protocol for second line therapy of squamous cell lung cancer.

Link

S1400F

A phase II study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY).

Link

S1400G

A phase II study of talazoparib (bmn 673) in patients with homologous recombination repair deficiency positive stage iv squamous cell lung cancer (lung-map sub-study).

Link

S1400K

A Phase II Study of ABBV-399 (Process II) in Patients with C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG- MAP SUB-STUDY)

Link

NHLBI-MDS

Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical data, blood, and tissue samples will be collected to establish a biorepository to facilitate the study of the natural history of MDS.

Link

E4512 (ALCHEMIST Component)

A phase III double-blind trial for surgically resected early stage non-small cell lung cancer: crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (alk) fusion protein.

Link

EA5142 (ALCHEMIST Component)

Adjuvant nivolumab in resected lung cancers (anvil) - a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers.

Link

Prostate

924

Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase III randomized trial.

Link

 

 

[Updated: 5/14/2018]

 

 

Copyright ©2019 Northeast Georgia Health System, Inc. | 743 Spring Street Gainesville, GA 30501 | (770) 219-9000